Nicholas Benedict
Switzerland, Z├╝rich
Board member, Juvabis AG


Nicholas Benedict is a Serial Entrepreneur active in Pharma & Biotechnology. 
Nicholas is Co-founder of Allecra Therapeutics a company focused on overcoming anti-microbial resistance (AMR), and holds several Board memberships including Juvabis AG, a company focused on alternative pathways to tackle AMR.
Nicholas gained a BA (Hons) in Philosophy from King‘s College London University and an MBA from the University of Manchester, UK.  Over his 25 years in the Pharma and Biotech industries Nicholas has a successful track record across the full spectrum of the Pharma/Biotech value chain, starting in finance in F. Hoffmann-La Roche before moving to marketing and sales followed by general management roles including responsibility for R&D. Positions included Head of one of Novartis’s 4 Global Business Units, Pharmaceuticals Country Manager at Novartis UK, Chief Commercial Officer at Basilea Pharmaceutica, where he successfully co-led the company’s follow-on offering raising over CHF320 million on the public equity markets, and CEO of Swiss start-up Lumavita AG.  Nicholas subsequently co-founded Allecra Therapeutics where, prior to handing over the CEO role at the end of 2018 after six years at the helm, he led four successful financing rounds, and progressed the lead compound from pre-clinical into Phase 3 with fast-track designation from the FDA.  Nicholas lives in Basel, Switzerland and holds both British and Swiss nationalities.

Processing. Please wait.